Lisa Bedell

943 total citations
23 papers, 677 citations indexed

About

Lisa Bedell is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, Lisa Bedell has authored 23 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 10 papers in Microbiology and 8 papers in Infectious Diseases. Recurrent topics in Lisa Bedell's work include Influenza Virus Research Studies (10 papers), Bacterial Infections and Vaccines (10 papers) and Pneumonia and Respiratory Infections (9 papers). Lisa Bedell is often cited by papers focused on Influenza Virus Research Studies (10 papers), Bacterial Infections and Vaccines (10 papers) and Pneumonia and Respiratory Infections (9 papers). Lisa Bedell collaborates with scholars based in United States, Germany and Canada. Lisa Bedell's co-authors include Peter Dull, Keith S. Reisinger, Nicola P. Klein, Annette Karsten, Roger Baxter, Tatjana Odrljin, Christopher Gill, S. Block, Lisa A. Jackson and James McCarty and has published in prestigious journals such as The Lancet, Neurology and Clinical Infectious Diseases.

In The Last Decade

Lisa Bedell

23 papers receiving 645 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Bedell United States 14 495 415 129 83 59 23 677
Sylvia H. Yeh United States 13 400 0.8× 242 0.6× 39 0.3× 71 0.9× 45 0.8× 26 530
Amit Bhavsar Belgium 9 303 0.6× 177 0.4× 53 0.4× 67 0.8× 35 0.6× 21 434
Chas DeBolt United States 11 378 0.8× 281 0.7× 41 0.3× 120 1.4× 113 1.9× 21 482
Frank Kowalzik Germany 9 237 0.5× 154 0.4× 22 0.2× 163 2.0× 65 1.1× 22 492
Satoko Ogita Japan 12 496 1.0× 312 0.8× 35 0.3× 46 0.6× 12 0.2× 31 597
Calil K. Farhat Brazil 10 284 0.6× 79 0.2× 54 0.4× 108 1.3× 41 0.7× 26 435
Jane Jelfs Australia 9 406 0.8× 379 0.9× 49 0.4× 49 0.6× 33 0.6× 12 488
Luis Barreto Canada 9 249 0.5× 201 0.5× 13 0.1× 116 1.4× 64 1.1× 15 364
Arianna Neri Italy 16 414 0.8× 463 1.1× 47 0.4× 40 0.5× 28 0.5× 55 579
Annette Fox Vietnam 7 194 0.4× 40 0.1× 106 0.8× 109 1.3× 14 0.2× 7 400

Countries citing papers authored by Lisa Bedell

Since Specialization
Citations

This map shows the geographic impact of Lisa Bedell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Bedell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Bedell more than expected).

Fields of papers citing papers by Lisa Bedell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Bedell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Bedell. The network helps show where Lisa Bedell may publish in the future.

Co-authorship network of co-authors of Lisa Bedell

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Bedell. A scholar is included among the top collaborators of Lisa Bedell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Bedell. Lisa Bedell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tindale, Lauren C., Jason S. Richardson, Deborah M. Anderson, et al.. (2025). Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 405(10487). 1353–1361. 10 indexed citations
3.
Richardson, Jason S., Deborah M. Anderson, Jason Mendy, et al.. (2025). Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 405(10487). 1343–1352. 7 indexed citations
4.
Richardson, Jason S., et al.. (2023). 2888. Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, ≥12 Years of Age. Open Forum Infectious Diseases. 10(Supplement_2). 3 indexed citations
5.
McCarty, James, Lisa Bedell, Jason Mendy, et al.. (2023). Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals. Vaccine. 41(42). 6146–6149. 4 indexed citations
6.
Bennett, Sean, James McCarty, Roshan Ramanathan, et al.. (2022). Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. The Lancet Infectious Diseases. 22(9). 1343–1355. 42 indexed citations
7.
McCarty, James, Lisa Bedell, Paul-André de Lame, et al.. (2021). Update on CVD 103-HgR single-dose, live oral cholera vaccine. Expert Review of Vaccines. 21(1). 9–23. 6 indexed citations
8.
McCarty, James, et al.. (2020). Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2–5 Years in the United States. American Journal of Tropical Medicine and Hygiene. 104(3). 861–865. 6 indexed citations
9.
McCarty, James, et al.. (2019). Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6–17 Years. American Journal of Tropical Medicine and Hygiene. 102(1). 48–57. 8 indexed citations
10.
Leroux‐Roels, Geert, Cathy Maes, Julie Willekens, et al.. (2016). A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women. Vaccine. 34(15). 1786–1791. 50 indexed citations
11.
Tregnaghi, Miguel, Pío López, Daniel Stamboulián, et al.. (2014). Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers. International Journal of Infectious Diseases. 26. 22–30. 24 indexed citations
12.
Nolan, Terry, Michael D. Nissen, Lisa Bedell, et al.. (2013). Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Human Vaccines & Immunotherapeutics. 10(2). 280–289. 21 indexed citations
13.
14.
Klein, Nicola P., et al.. (2011). Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants. The Pediatric Infectious Disease Journal. 31(1). 64–71. 45 indexed citations
15.
Stamboulián, Daniel, Gustavo Lopardo, Pío López, et al.. (2010). Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. International Journal of Infectious Diseases. 14(10). e868–e875. 41 indexed citations
16.
17.
Halperin, Scott A., Anil Kumar Gupta, Robert Jeanfreau, et al.. (2010). Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine. 28(50). 7865–7872. 44 indexed citations
18.
Black, Steven, Nicola P. Klein, Jay Shah, et al.. (2009). Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age. Vaccine. 28(3). 657–663. 49 indexed citations
19.
Jackson, Lisa A., Roger Baxter, Keith S. Reisinger, et al.. (2009). Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents. Clinical Infectious Diseases. 49(1). e1–e10. 87 indexed citations
20.
Mohr, David C., et al.. (1999). Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Multiple Sclerosis Journal. 5(3). 192–197. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvia H. Yeh Breakdown of academic impact, for papers by Amit Bhavsar Breakdown of academic impact, for papers by Chas DeBolt Breakdown of academic impact, for papers by Frank Kowalzik Breakdown of academic impact, for papers by Satoko Ogita Breakdown of academic impact, for papers by Calil K. Farhat Breakdown of academic impact, for papers by Jane Jelfs Breakdown of academic impact, for papers by Luis Barreto Breakdown of academic impact, for papers by Arianna Neri Breakdown of academic impact, for papers by Annette Fox
Rankless by CCL
2026